Vol 72, No 2 (2021)
Clinical vignette
Published online: 2021-01-19

open access

Page views 925
Article views/downloads 480
Get Citation

Connect on Social Media

Connect on Social Media

Efficacy of multimodal anticancer therapy in the course of pancreatic neuroendocrine carcinoma

Helena Zwinczewska12, Marta Opalinska2, Anna Sowa-Staszczak21, Anna Kurzynska21, Agnieszka Stefanska2, Alicja Hubalewska-Dydejczyk21
Pubmed: 33619719
Endokrynol Pol 2021;72(2):183-184.

Abstract

Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file

References

  1. Zhang MY, He Du, Zhang S. Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment. World J Gastrointest Oncol. 2020; 12(7): 705–718.
  2. Lokesh KN, Anand A, Lakshmaiah KC, et al. Clinical profile and treatment outcomes of metastatic neuroendocrine carcinoma: A single institution experience. South Asian J Cancer. 2018; 7(3): 207–209.
  3. Lorenzoni A, Capozza A, Artale S, et al. Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma. Clin Nucl Med. 2018; 43(7): 506–508.
  4. Alese OB, Jiang R, Shaib W, et al. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2020; 25(5): e877.
  5. Rogowski W, Wachuła E, Gorzelak A, et al. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis. Endokrynol Pol. 2019; 70(4): 313–317.
  6. Montanier N, Joubert-Zakeyh J, Pétorin C, et al. The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature. Medicine (Baltimore). 2017; 96(6): e6062.